NLRP3 and obesity due to melanocortin 4 receptor deficiency: Although mechanistic insights continue to evolve, the integration of SGLT2 inhibitors into AF management holds significant promise, particularly in patients with diabetes, heart failure, or obesity—conditions strongly associated with heightened NLRP3 activity.